Harvard Bioscience Inc. (HBIO) Stock Price Up 2.3%
Harvard Bioscience Inc. (NASDAQ:HBIO)’s share price rose 2.3% on Tuesday . The company traded as high as $3.15 and last traded at $3.10, with a volume of 66,164 shares traded. The stock had previously closed at $3.03.
Separately, Zacks Investment Research upgraded shares of Harvard Bioscience from a “sell” rating to a “hold” rating in a research report on Monday, March 28th.
The firm’s market cap is $105.61 million. The stock’s 50 day moving average price is $3.23 and its 200-day moving average price is $3.00.
Harvard Bioscience (NASDAQ:HBIO) last released its quarterly earnings results on Thursday, May 12th. The company reported $0.05 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.02 by $0.03. The company earned $27 million during the quarter, compared to analyst estimates of $26 million. On average, analysts forecast that Harvard Bioscience Inc. will post $0.18 EPS for the current year.
An institutional investor recently raised its position in Harvard Bioscience stock. Glacier Peak Capital LLC raised its stake in Harvard Bioscience Inc. (NASDAQ:HBIO) by 6.5% during the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 452,258 shares of the company’s stock after buying an additional 27,514 shares during the period. Harvard Bioscience comprises 1.0% of Glacier Peak Capital LLC’s holdings, making the stock its 27th largest position. Glacier Peak Capital LLC owned 1.33% of Harvard Bioscience worth $1,569,000 at the end of the most recent quarter.
Harvard Bioscience, Inc is a developer, manufacturer and marketer of a range of specialized products, apparatus and scientific instruments. The Company’s products are used to advance life science research at pharmaceutical and biotechnology companies, universities and government laboratories across the world.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.